- Medical Oncology
David H. Vesole is director of the Myeloma Program at MedStar Georgetown University Hospital and a professor of Medicine at Georgetown University. Concurrently, he is co-director of the Myeloma Division and director of Myeloma Research at the John Theurer Cancer Center at Hackensack University Medical Center. Previously, Dr. Vesole was director of the BMT Program at Loyola University in Maywood, IL, an attending physician at St. Vincent's Comprehensive Cancer Center in New York, and Professor of Medicine and Clinical Director of the Blood and Marrow Transplant Program at the Medical College of Wisconsin in Milwaukee.
Board certified in medical oncology and hematology and a Fellow of the American College of Physicians, Dr. Vesole is active in several professional organizations including the American Society for Blood and Marrow Transplantation, the American Society of Clinical Oncology and the American Society of Hematology. He previously served as co-chair of the Eastern Cooperative Oncology Group Myeloma Committee and the Center for International Blood and Marrow Transplant Research (CIBMTR) Plasma Cell Disorder Committee where he currently sits on the Nominating Committee. He is an inspector for the Foundation for the Accreditation of Cellular Therapy (FACT) and serves on FACT's Clinical Standards, Accreditation and Data Management Task Force Committees. Additionally, Dr. Vesole is a member of the International Myeloma Foundation Scientific Advisory Board and the International Myeloma Working Group, a board member of the New York City chapter of the Leukemia and Lymphoma Society, and a reviewer, Leukemia & Lymphoma Society Translational Grant Review Committee.
Dr. Vesole has authored more than 200 articles in peer-reviewed medical journals and book chapters. He also serves as a reviewer for several journals, including the American Journal of Hematology, Blood, Journal of Clinical Oncology, Biology of Blood and Marrow Transplant, Bone Marrow Transplant, Leukemia, Leukemia and Lymphoma and Clinical Lymphoma Myeloma & Leukemia. Dr. Vesole has presented his research at medical meetings and symposia nationally and internationally.
David H. Vesole earned a medical degree at Northwestern University and a doctorate in immunology and microbiology at the Medical University of South Carolina. His postdoctoral medical training included a residency in internal medicine and a fellowship in Hematology and Oncology at University of Iowa Hospitals and Clinics.
The field of multiple myeloma is continuously evolving, with marked improvements in outcomes in the past 10 years. Our program provides treatment options to patients from initial diagnosis to recurrent disease. Since the biology of myeloma is unique for each patient, we tailor treatments to each individual, ranging from conventional agents to participation in clinical trials. Our most recent focus is on harnessing the power of the immune system to provide patient-specific treatments, targeting specific pathways for disease control. Ultimately, even if the disease is not cured, we strive to offer sequential therapies that result in changing myeloma from an incurable disease to one that is chronic, resulting in prolonged survival and excellent quality of life.
- Fellowship Program: University of Iowa Hospitals and Clinics (1990)
- Residency Program: University of Iowa Hospitals and Clinics (1987)
- Internship Program: University of Iowa Hospitals and Clinics (1985)
- Medical School: Northwestern University Medical School (1984)
- Board Certification: American Board of Internal Medicine, Internal Medicine
Rodriguez TE, Hari P, Stiff PJ, Smith SE, Vesole DH. Busulfan, Melphalan, and Bortezomib versus High Dose Melphalan AS A Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma In press. Biol Blood Marrow Transplant
Vesole DH, Bilotti E, Richter JR, McNeill A, McBride L, Raucci L, Anand P, Bednarz U, Ivanovski K, Smith J, Batra V, Aleman A, Sims T, Guerrero L, Mato A, and Siegel DSS. Phase 1 study of carfilzomib, lenalidomide, vorinostat and dexamethasone (QUAD) in patients with relapsed and/or refractory multiple myeloma. Br J Haematol. 2015;171:52-9
Richardson PG, Xie W, Jagannath S, … Vesole DH… Anderson KC. A Phase II trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma. Blood. 2014; 123:1461-9.
Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, et al. Autologous haematopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncology. 2011; 12: 1195-1203.
Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson K. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 2014; 123:3208-9.
Dytfeld D, Jasielec J, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R, Jakubowiak AJ. Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica. 2014;99:e162-4
- 3800 Reservoir Road NorthwestWashington, DC 20007
- MedStar Georgetown University Hospital